Comparison of [18F]-Tracers in various experimental tumor models by PET imaging and identification of an early response biomarker for the novel microtubule stabilizer patupilone

Molecular Imaging and Biology

Volumn 11, Issue 5, 2009, Pages 308-321

  Ebenhan, T ^a   Honer, Michael ^b   Ametamey, S M ^b   Schubiger, P A ^b   Becquet, M ^a   Ferretti, S ^a   Cannet, C ^a   Rausch, M ^a   McSheehy, P M J ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

^b ETH ZURICH   (Switzerland)

Author keywords

18F FCH; 18F FDG; 18F FET; 18F FLT; Biomarker; Patupilone; PET; Quad HIDAC; Tumor xenografts

Indexed keywords

CASPASE 3; CYCLINE; EPOTHILONE B; FLUORODEOXYGLUCOSE F 18; KI 67 ANTIGEN; 2',3' DIDEOXYNUCLEOSIDE DERIVATIVE; 3' FLUOROTHYMIDINE; ANTINEOPLASTIC AGENT; CHOLINE; DIAGNOSTIC AGENT; DRUG DERIVATIVE; EPOTHILONE DERIVATIVE; FLUORINE; FLUOROCHOLINE; O (18F)FLUOROMETHYL L TYROSINE; O-(18F)FLUOROMETHYL-L-TYROSINE; RADIOPHARMACEUTICAL AGENT; TUBULIN MODULATOR; TYROSINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BODY WEIGHT; BREAST CARCINOMA; COLON CARCINOMA; CORRELATION ANALYSIS; DOSE RESPONSE; DRUG TOLERABILITY; DRUG UPTAKE; FEMALE; FIBROSARCOMA; GLIOBLASTOMA; HUMAN; HUMAN CELL; IMAGE QUALITY; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; MOUSE; NONHUMAN; OVARY CARCINOMA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSTATE CARCINOMA; RAT; TUMOR GROWTH; TUMOR XENOGRAFT; ANIMAL; CANCER TRANSPLANTATION; CELL PROLIFERATION; COMPARATIVE STUDY; DISEASE MODEL; DRUG EFFECT; IMAGE PROCESSING; METABOLISM; METHODOLOGY; NEOPLASM; NUDE MOUSE; PATHOLOGY; REPRODUCIBILITY; SCINTISCANNING; TUMOR CELL LINE; WHOLE BODY IMAGING; XENOGRAFT;

ANIMALIA; MURINAE; RODENTIA;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; CHOLINE; DIDEOXYNUCLEOSIDES; DISEASE MODELS, ANIMAL; EPOTHILONES; FEMALE; FLUORINE RADIOISOTOPES; FLUORODEOXYGLUCOSE F18; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; RATS; REPRODUCIBILITY OF RESULTS; TRANSPLANTATION, HETEROLOGOUS; TUBULIN MODULATORS; TYROSINE; WHOLE BODY IMAGING;

EID: 68449101077     PISSN: 15361632     EISSN: 18602002     Source Type: Journal    
DOI: 10.1007/s11307-009-0216-1     Document Type: Article

References (53)

1. Phelps ME (2000) Positron emission tomography provides molecular imaging of biological processes. Proc Natl Acad Sci U S A 97:9226-9233
2. 18F]fluorodeoxyglucose and positron emission tomography. Neurology 32:1323-1329
3. Hicks RJ, Kalff V, MacManus MP et al (2001) 18 F-FDG PET provides high-impact and powerful prognostic stratification in staging newly diagnosed non-small cell lung cancer. J Nucl Med 42:1596-1604
4. Weber WA (2005) Use of PET monitoring cancer therapy and for predicting outcome. J Nucl Med 46:983-995
5. Lammertsma AA, Hoekstra CJ, Giaccone G et al (2006) How should we analyse FDG PET studies for monitoring tumour response. Eur J Nucl Med Mol Imaging 33:16-21
6. Kenny LM, Aboagye EO, Price RM (2004) Positron emission tomography imaging of cell proliferation in oncology. Clin Onc 16:176-185
7. Spaeth N, Wyss MT, Weber B et al (2004) Uptake of 18F-fluorocholine, 18F-fluoroethyl-l-tyrosine, and 18F-FDG in acute cerebral radiation injury in the rat: Implications for separation of radiation necrosis from tumour recurrence. J Nucl Med 45:1931-1938
8. Katz-Brull R, Degani H (1996) Kinetics of choline transport and phosphorylation in human breast cancer cells: NMR application of the zero trans method. Anticancer Res 16:1375-1380
9. Belt JA, Marina NM, Phelps DA et al (1993) Nucleoside transport in normal and neoplastic cells. Adv. Enzyme Regul 33:235-252
10. Kong W, Engel K, Wang J (2004) Mammalian nucleoside transporters. Curr Drug Metab 5:63-84
11. Shields AF, Grierson JR, Dohmen BM et al (1998) Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nat Med 4:1334-1336
12. Grierson JR, Shields AF (2000) Radiosynthesis of 3′-deoxy-3′-[18F]fluorothymidine: [18F]FLT for imaging of cellular proliferation in vivo. Nucl Med Biol 27:143-156
13. Rasey JS, Grierson JR, Wiens LW et al (2002) Validation of FLT uptake as a measure of thymidine kinase-1 activity in A549 carcinoma cells. J Nucl Med 438:1210-1217
14. 18F-FLT versus 18 F-FDG. J Nucl Med 44:1432-1434
15. 18F]FLT; portrait of a proliferation marker. Eur J Nucl Med 29:165-169
16. Shields AF (2006) Positron emission tomography measurement of tumour metabolism and growth: Its expanding role in oncology. Mol Imaging Biol 8:141-150
17. Kenny LM, Aboagye EO, Price PM (2004) Positron emission tomography imaging of cell proliferation in oncology. Clin Oncol 16:176-185
18. 18 F]fluoroethyl)-l-tyrosine in vitro and in vivo. J Nucl Med 40:1367-1373
19. 18F]fluoroethyl)-l-tyrosine for tumour imaging. J Nucl Med 40:205-212
20. 18 F-fluoroethyl)-l-tyrosine in peripheral tumours: First clinical results. J Nucl Med 46:411-416
21. 18 F]fluoroethyl)-l-tyrosine: Uptake mechanisms and clinical applications. Nucl Med Biol 33:287-294
22. 131 I-SIP(L19), a marker of angiogenesis. J Nucl Med 48:608-614
23. 18F]FDG as PET probes in a brain tumour-bearing animal model. Nucl Med Biol 32:367-375
24. 18 F]fluoroethyl)-l-tyrosine (FET): A tracer for differentiation of tumour from inflammation in murine lymph nodes. J Nucl Med 29:1039-1046
25. 18F-labeled choline analogs as oncologic PET tracers. J Nucl Med 42:1805-1814
26. 18F]fluorodeoxyglucose for positron emission tomography of androgen dependent and androgen independent prostate cancer. J Urol 168:273-280
27. Hara T, Kosaka N, Kishi H (1998) PET imaging of prostate cancer using carbon-11-choline. J Nucl Med 39:990-995
28. Shinoura N, Nishijima M, Hara T et al (1997) Brain tumours: Detection with C-11 choline PET. Radiology 202:497-503
29. Hara T, Inagaki K, Kosaka N et al (2000) Sensitive detection of mediastinal lymph node metastasis of lung cancer with 11C-choline PET. J Nucl Med 41:1507-1513
30. Hara T, Bansal A, DeGrado TR (2006) Choline transporter as a novel target for molecular imaging of cancer. Mol Imaging 5:498-509
31. McSheehy PMJ Allegrini PR Ametamey SM et al (2005) The anticancer agent RAD001 rapidly inhibits 18 F-FDG uptake by sensitive but not resistant tumours. 52nd Meeting Society Nuclear Medicine, abstract 1238
32. Altmann K-H (2003) Epothilone B and its analogs - a new family of anticancer agents. Mini Rev Med Chem 3:149-158
33. Goodin S, Kane MP, Rubin EH (2004) Epothilones: Mechanism of action and biologic activity. J Clin Oncol 22:2015-2025
34. Ferretti S, Allegrini PR, O'Reilly T et al (2005) Patupilone induced vascular disruption in orthotopic rodent tumour models detected by magnetic resonance imaging and interstitial fluid pressure. Clin Cancer Res 11:7773-7784
35. 18 F]fluorothymidine positron emission tomography: The effect of cisplatin on a fibrosarcoma tumour model in vivo. Cancer Res 65:4202-4010
36. N2 reactions catalyzed by protic solvents: Facile fluorination for isotopic labeling of diagnostic molecules. J Am Chem Soc 128:16394-16397
37. Rudin M, McSheehy PMJ, Allegrini PR et al (2005) PTK787/ZK222584, a tyrosine kinase inhibitor of vascularendothelial growth factor receptor, reduces uptake of the contrast agent GdDOTA by murine orthotopic B16/BL6 melanoma tumours and inhibits their growth in vivo. NMR Biomed 18:308-332
38. Missimer J, Madi Z, Honer M et al (2004) Performance evaluation of the 16-module quad-HIDAC small animal PET camera. Phys Med Biol 49:2069-2081
39. Jeavons AP, Chandler RA, Dettmar CAR (1999) A 3D HIDAC-PET camera with submillimetre resolution for imaging small animals. IEEE Trans Nucl Sci 46:468-473
40. Reader AJ, Erlandsson K, Flower MA et al (1998) Fast accurate iterative reconstruction for low-statistics positron volume imaging. Phys Med Biol 43:835-846
41. Mikolajczyk K, Szabatin M, Rudnicki P et al (1998) A JAVA environment for medical image data analysis: Initial application for brain PET quantification. Med Inform (Lond) 23:207-214
42. O'Reilly T, Wartmann M, Brueggen J et al (2009) Pharmacokinetic profile of the novel microtubule stabilizer patupilone in tumour-bearing rodents and comparison of anti-cancer activity with other MTS in multi-drug resistant human colon tumour cells in vitro and in vivo. Cancer Chemother. Pharmacol 62(6):1045-1054
43. McSheehy PMJ, Robinson S, Ojugo A et al (1998) Carbogen breathing increases 5-fluorouracil uptake and cytotoxicity in hypoxic RIF-1 tumours: A magnetic resonance study in vivo. Cancer Res 58:1185-1194
44. Lee L, Sharma S, Morgan B et al (2006) Biomarkers for assessment of pharmacologic activity for a vascular endothelial growth factor (VEGF) receptor inhibitor, PTK787/ZK 222584 (PTK/ZK): Translation of biological activity in a mouse melanoma metastases model to phase I studies in patients with advanced colorectal cancer with liver metastases. Cancer Chemother Pharmacol 7:761-771
45. Robinson S, Rijken P, Howe F et al (2003) Assessment of tumour vascular development and function by susceptibility MRI methods and immunohistochemistry. J Magn Res 17:445-454
46. Cooper RA, Carrington BM, Loncaster JA et al (2000) Tumour oxygenation levels correlate with dynamic contrast-enhanced magnetic resonance imaging parameters in carcinoma of the cervix. Radiother Oncol 57:53-59
47. 18F]fluorodeoxyglucose positron emission tomography imaging. Clin Cancer Res 10:2245-2252
48. 18F-FDG PET studies in mice. J Nucl Med 47:999-1006
49. 18F-FDG biodistribution and insulin levels in tumor-bearing mice. J Nucl Med 46:1531-1536
50. Apisarnthanarax S, Alauddin MM, Mourtada F et al (2006) Early detection of chemoradioresponse in esophageal carcinoma by 3′-Deoxy-3′-3H-fluorothymidine using preclinical tumour models. Clin Cancer Res 12:4590-4597
51. Landberg G, Tan EM, Roos G (1990) Flow cytometric multiparameter analysis of proliferating cell nuclear antigen/cyclin and Ki-67 antigen: a new view of the cell cycle. Exp Cell Res 187(1):111-118
52. Quiñones-Hinojosa A, Sanai N, Smith JS (2005) Techniques to assess the proliferative potential of brain tumours. J Neurooncol 74:19-30
53. Eriksson S, Kierdaszuk B, Munch-Petersen B et al (1991) Comparison of the substrate specificities of human thymidine kinase 1 and 2 and deoxycytidine kinase toward antiviral and cytostatic nucleoside analogs. Biochem Biophys Res Commun 176:586-592